Citadel Advisors
GLUE icon

Citadel Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Citadel Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.19M Buy
254,518
+208,255
+450% +$3.98M ﹤0.01% 4639
2025
Q4 		$725K Sell
46,263
-4,746
-9% -$64K ﹤0.01% 8129
2025
Q3 		$378K Sell
51,009
-26,909
-35% -$143K ﹤0.01% 9808
2025
Q2 		$351K Buy
+77,918
New +$348K ﹤0.01% 9436
2025
Q1 		– Sell
-778,386
Closed -$4.77M – 14886
2024
Q4 		$5.4M Sell
778,386
-380,583
-33% -$2.86M ﹤0.01% 3834
2024
Q3 		$6.14M Buy
1,158,969
+163,026
+16% +$823K ﹤0.01% 3622
2024
Q2 		$3.72M Buy
995,943
+15,704
+2% +$80.1K ﹤0.01% 4222
2024
Q1 		$6.91M Sell
980,239
-3,546
-0.4% -$21K ﹤0.01% 3466
2023
Q4 		$5.56M Buy
983,785
+153,175
+18% +$601K ﹤0.01% 3633
2023
Q3 		$3.98M Buy
830,610
+58,846
+8% +$379K ﹤0.01% 4022
2023
Q2 		$5.29M Buy
771,764
+1,763
+0.2% +$11.4K ﹤0.01% 3570
2023
Q1 		$6M Sell
770,001
-204,194
-21% -$1.42M ﹤0.01% 3515
2022
Q4 		$7.41M Buy
974,195
+21,239
+2% +$177K ﹤0.01% 3238
2022
Q3 		$7.79M Buy
952,956
+833,124
+695% +$7.65M ﹤0.01% 3130
2022
Q2 		$1.16M Buy
119,832
+72,642
+154% +$730K ﹤0.01% 6691
2022
Q1 		$662K Sell
47,190
-2,091
-4% -$29K ﹤0.01% 8711
2021
Q4 		$1.01M Buy
49,281
+11,732
+31% +$246K ﹤0.01% 7941
2021
Q3 		$836K Sell
37,549
-58,243
-61% -$1.67M ﹤0.01% 8588
2021
Q2 		$2.17M Buy
+95,792
New +$1.95M ﹤0.01% 6391

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's GLUE Position: Q1 2026 in Review

Citadel Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 450% in Q1 2026, buying an estimated $3.98M and bringing the position to 254,518 shares worth $4.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4639.

Citadel Advisors first reported a position in GLUE in Q2 2021 and has held it in 19 quarters since. The position peaked at $7.79M in Q3 2022. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Citadel Advisors held 254,518 shares of Monte Rosa Therapeutics worth $4.19M as of Q1 2026.
  • Citadel Advisors bought 208,255 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.98M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4639 holding.
  • Citadel Advisors first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Monte Rosa Therapeutics position peaked at $7.79M in Q3 2022.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.